We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

87 hedge funds and large institutions have $846M invested in Rhythm Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

18% more funds holding

Funds holding: 74 → 87 (+13)

16% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 25

1% less capital invested

Capital invested by funds: $851M → $846M (-$4.87M)

2.35% less ownership

Funds ownership: 92% → 89.65% (-2.4%)

Holders
87
Holders Change
+13
Holders Change %
+17.57%
% of All Funds
1.88%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.13%
New
17
Increased
29
Reduced
25
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.15M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2M
3
HP
Harbourvest Partners
Massachusetts
+$1.44M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.26M
5
SIM
Spark Investment Management
New York
+$1.11M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$28.7M
2
O
OrbiMed
New York
-$4.06M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.89M
4
RCM
RA Capital Management
Massachusetts
-$1.88M
5
Citigroup
Citigroup
New York
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
76
Marshall Wace North America
New York
$33K +$34.3K +1,195 New
TRCT
77
Tower Research Capital (TRC)
New York
$30K +$24.7K +859 +364%
AIP
78
Ameritas Investment Partners
Nebraska
$28K – – –
KPW
79
Kore Private Wealth
New York
$14K – – –
Twin Tree Management
80
Twin Tree Management
Texas
$8K +$8.13K +283 New
Rockefeller Capital Management
81
Rockefeller Capital Management
New York
$7K +$7.16K +249 New
Daiwa Securities Group
82
Daiwa Securities Group
Japan
$6K -$2.33K -81 -27%
UBS Group
83
UBS Group
Switzerland
$5K -$293K -10,178 -98%
AG
84
Advisor Group
Arizona
$5K +$5.75K +200 New
US Bancorp
85
US Bancorp
Minnesota
$3K +$2.85K +99 New
Citadel Advisors
86
Citadel Advisors
Florida
– -$391K -14,521 Closed
BFM
87
Boothbay Fund Management
New York
– -$296K -11,000 Closed
D.E. Shaw & Co
88
D.E. Shaw & Co
New York
– -$295K -10,982 Closed
MAM
89
Meeder Asset Management
Ohio
– -$16K -583 Closed
Bank of Montreal
90
Bank of Montreal
Ontario, Canada
– -$6.18K -215 -100%
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
– +$86 +3 +150%
1 2 3
4

RYTM Hedge Fund Activity: Q1 2019 in Review

87 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2019, worth a combined $846M — down 0.57% from $851M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RYTM positions and 4 closed out — a net gain of 13 holders — while 29 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $6.15M. The largest seller was TRV GP, cutting an estimated $28.7M.

  • 87 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2019, up from 74 in Q4 2018.
  • Funds reported $846M of Rhythm Pharmaceuticals stock for Q1 2019, down 0.57% quarter-over-quarter.
  • 17 funds opened new Rhythm Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $6.15M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2019 was TRV GP, an estimated $28.7M sold.

Based on aggregated 13F filings for Q1 2019.